دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Table of Contents
doi : 10.1016/S0923-7534(21)02190-6
Volume 32, Issue 9, September 2021, Pages i-ii
Genome instability and success of checkpoint inhibitors: form and levels matter
S.Derks12
Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future
S.P.L.SawD.S.W.Tan
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust
M.J.Piccart12K.Kalinsky3R.Gray4W.E.Barlow5C.Poncet6F.Cardoso7E.Winer8J.Sparano9
Right to Try, expanded access use, Project Facilitate, and clinical trial reform
N.K.Reddy1V.Subbiah234
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S.Rao1M.G.Guren2K.Khan34G.Brown5A.G.Renehan6S.E.Steigen7E.Deutsch8E.Martinelli9D.Arnold10ESMO Guidelines Committee
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
M.Reck1D.P.Carbone2M.Garassino3F.Barlesi45
Practical considerations in screening for genetic alterations in cholangiocarcinoma
T.S.Bekaii-Saab1J.Bridgewater2N.Normanno3
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
K.Shitara1M.Özgüroğlu2Y.-J.Bang3M.Di Bartolomeo4M.Mandalà 5M.-H.Ryu6C.Caglevic7H.C.Chung8K.Muro9E.Van Cutsem10J.Kobie11R.Cristescu11D.Aurora-Garg11J.Lu11C.-S.Shih11D.Adelberg11Z.A.Cao11C.S.Fuchs12
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
S.Sugawara1†J.-S.Lee2†J.-H.Kang3H.R.Kim4N.Inui5T.Hida6K.H.Lee7T.Yoshida8H.Tanaka9C.-T.Yang10M.Nishio11Y.Ohe8T.Tamura12N.Yamamoto13C.-J.Yu14H.Akamatsu13Y.Namba15N.Sumiyoshi16K.Nakagawa17
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A.Bardia1S.M.Tolaney2K.Punie3D.Loirat4M.Oliveira5K.Kalinsky67A.Zelnak8P.Aftimos9F.Dalenc10S.Sardesai11E.Hamilton12P.Sharma13S.Recalde14E.C.Gil15T.Traina16J.O’Shaughnessy17J.Cortes18M.Tsai19…S.A.Hurvitz27
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A.A.Hamid12H.-C.Huang3V.Wang4Y.-H.Chen4F.Feng5R.Den6G.Attard7E.M.Van Allen1P.T.Tran8D.E.Spratt9R.Dittamore3E.Davicioni3G.Liu10R.DiPaola11M.A.Carducci8C.J.Sweeney1
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
E.A.Klein1D.Richards2A.Cohn3M.Tummala4R.Lapham5D.Cosgrove6G.Chung7J.Clement8J.Gao9N.Hunkapiller9A.Jamshidi9K.N.Kurtzman9M.V.Seiden10C.Swanton1112M.C.Liu13
Deep learning for diagnosis and survival prediction in soft tissue sarcoma
S.Foersch1M.Eckstein2D.-C.Wagner1F.Gach1A.-C.Woerl13J.Geiger13C.Glasner13S.Schelbert1S.Schulz1S.Porubsky1A.Kreft1A.Hartmann2A.Agaimy2W.Roth1
TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061
M.B.FooteS.B.MaronA.CercekG.ArgilésB.RousseauL.A.DiazJr.
Adjuvant nivolumab for the management of pathological residual disease in esophageal or junctional tumors: a word of caution
P.K.Garg1R.Kumar2P.Dixit3
Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit
E.C.Smyth1†V.Gambardella23†A.Cervantes23‡T.Fleitas23‡
Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine
K.Altundag
Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study
E.P.Mamounas
Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer
R.Iacovelli1C.Ciccarese12G.Tortora12
Real-world prevalence across 159Â 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
D.Fabrizio1R.Cristescu2L.Albacker1A.Snyder2A.Ward1J.Lunceford2D.Aurora-Garg2F.Jin2J.Hopkins1E.Rubin2P.Hegde1
Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.
D.J.McGrail1P.G.Pilié2N.U.Rashid34L.Voorwerk5M.Slagter678M.Kok59E.Jonasch2M.Khasraw10A.B.Heimberger1112N.T.Ueno13R.Ferrarotto14J.T.Chang1516S.-Y.Lin1
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
P.Schmid1J.Cortes2R.Dent3L.Pusztai4H.McArthur5S.Kümmel6J.Bergh7C.Denkert8Y.H.Park9R.Hui10N.Harbeck11M.Takahashi12M.Untch13P.A.Fasching14F.Cardoso15Y.Ding16K.Tryfonidis17G.Aktan17…J.O’Shaughnessy18
Corrigendum to ‘Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer’: [Annals of Oncology Volume 31, Issue 1, January 2020, Pages 103-114]
J.M.Genkinger12K.Wu3M.Wang456D.Albanes7A.Black7P.A.van den Brandt8K.A.Burke1M.B.Cook7S.M.Gapstur9G.G.Giles1011E.Giovannucci346G.G.Goodman12P.J.Goodman13N.Håkansson14T.J.Key15S.Männistö16L.Le Marchand17L.M.Liao7…S.A.Smith-Warner34
